Navigation Links
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
Date:2/21/2008

Netherlands, as the reference member state for approval in the EU via the decentralized procedure, on December 12, 2007.

- INTUNIV(TM) (previously known as SPD503) - ADHD - A non-stimulant "non-scheduled" medication for the treatment of ADHD. In June 2007 Shire received an approvable letter from the FDA for INTUNIV. Shire is in discussions with the FDA regarding additional clinical work which is designed to enhance the label. While the precise timing of the approval of INTUNIV is unknown, Shire now anticipates that launch will occur in H2 2009.

- SPD465 - ADHD - In May 2007 Shire received an approvable letter from the FDA. Shire is not currently taking any steps to move this product towards approval.

- FOSRENOL - Hyperphosphatemia - On October 16, 2007 the FDA Cardiovascular and Renal Drugs Advisory Committee recommended by a majority vote the use of phosphate binders, including FOSRENOL, to treat hyperphosphatemia in CKD stage 4 patients. Shire is working with the FDA to explore the regulatory pathway to approval for use in pre-dialysis patients.

- LIALDA/MEZAVANT - Phase 3 worldwide clinical trials investigating the use of the product for the treatment of diverticulitis, a colonic disease, were initiated in 2007.

- ELAPRASE - for Hunter syndrome patients with significant central nervous system symptoms - In December 2007 Shire completed all pre-clinical work and filed an Investigational New Drug ("IND") application. The IND was accepted by the FDA on January 23, 2008.

- Velaglucerase alfa (GA-GCB) - Gaucher disease - A worldwide Phase 3 clinical program was initiated in 2007 and is ongoing. It is anticipated that this development program will support filing of velaglucerase alfa from H2 2009.

- Whilst a number of preclinical products are underway in early stage development, Shire has discontinued the following projects: SPD491 (a pain product), SPD493 (formerly known as Valrocemide), SPD500 (Tissue protective cytoki
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Correction Re Website
2. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
3. Shire Engages Palio
4. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
5. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire plc: Board Changes
9. David Mott Appointed Non Executive Director at Shire
10. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
11. Shire Divests Non-Core Product Portfolio to Almirall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  ECC West Africa, LLC (ECC) signed ... with University College Hospital (UCH) Ibadan Board of Management ... finance, design, construct, and operate and maintain a new, ... . Under the first of the 4-phase project, ECC ... funding applications. UCH Ibadan intends to finance and develop ...
(Date:7/24/2014)... computers have yet to materialise. Yet, scientists are ... such computers faster. One such approach relies on ... by applying an electric field. A new study ... coupled quantum dots (TQDs) with electrical impulses can ... example, should TQDs be used as quantum information ...
(Date:7/24/2014)... 24, 2014 Research and Markets ... Culture Market 2014-2018" report to their offering.  ... culture is the in vitro growth of plant or ... studies, and biopharmaceutical production. Cell culture is a crucial ... instruments and cell culture consumables are necessary for the ...
(Date:7/24/2014)... July 24, 2014 SRI International has been ... National Institute of Allergy and Infectious Diseases (NIAID), part ... development of potential therapies for HIV infection and AIDS. ... HIV and AIDS and the complications and opportunistic infections ... preventing sexual transmission of HIV. According ...
Breaking Biology Technology:ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
... Health Robotics today announced,audited results for FY2008 ending ... orders, revenue, earnings and cash flow. , ... million, a 161% increase year-over-year as,the company began ... indirect,sales-channel franchise fee model, recurring revenue recognition, zero ...
... MESA, Calif., April 14 Oxygen Biotherapeutics, ... it has reached a development and commercial ... One(R) Global Pharmaceutical Services business unit to ... perfluorocarbon (PFC) therapeutic oxygen carrier. Oxycyte will ...
... April 14 BioVex Inc, a company developing ... and infectious disease, announced today that its OPTiM (OncoVEX Pivotal ... previously treated patients with Stage III and Stage IV melanoma ... U.S. with sites in the United Kingdom, Germany and Australia ...
Cached Biology Technology:Health Robotics Reports Triple-Digit-Growth Across All Financial Metrics in Fiscal Year 2008 2Health Robotics Reports Triple-Digit-Growth Across All Financial Metrics in Fiscal Year 2008 3Health Robotics Reports Triple-Digit-Growth Across All Financial Metrics in Fiscal Year 2008 4Health Robotics Reports Triple-Digit-Growth Across All Financial Metrics in Fiscal Year 2008 5Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs 2BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 2BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 3BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 4
(Date:7/28/2014)... killers to prevent and treat HIV infection has been ... these molecules can arouse as they get rid of ... the Weizmann Institute and the National Institutes of Health ... molecules interferons around the time of infection ... disease. Their research appeared in Nature . ...
(Date:7/28/2014)... RENO Norwegian explorer Roald Amundsen became the first ... 1911. More than 100 years later, an international team ... Research Institute (DRI) have proven that air pollution from ... 16 ice cores collected from widely spaced locations around ... created the most accurate and precise reconstruction to date ...
(Date:7/27/2014)... Scientists have discovered a new species of mayfly in the ... of India. In fact, this is the first time that ... been collected in peninsular India. , The new species, called ... T. Soldan for his substantial contribution to the understanding of ... authors of a study that describes the new mayfly in ...
Breaking Biology News(10 mins):Interfering with interferon 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3
... new gasoline. But where,s the nearest "gas" station ... vehicle? Will hydrogen stations be strategically convenientlocated on ... What marketing development obstacles need to be overcome if ... and gain widespread acceptance? According to an article ...
... the effect of nutrients on muscle maintenance in the hope ... we get old. The researchers, based at the School ... know what sort of exercise we can take and what ... of skeletal muscle with ageing. The team from the ...
... from Tel Aviv University, the saying may be more than ... have an ability to "see" colors and shapes with their ... of a new book, Advances in Information Optics and ... optical imaging technology that beats the limitations of today,s lens-based ...
Cached Biology News:The viability of hydrogen transportation markets: Chicken or egg? 2A stronger future for the elderly 2Seeing through the skin 2
... medium was originally formulated to support the ... emperor gum moth,Antherea eucalypti. The medium is ... closely resembleAnthereahemolymph. The cell lines established by ... continuous lines developed. The basal medium, when ...
... all Programmable and Digital Orbital Shaker. Our durable, ... to make every day use even easier. This ... up to 4 different programs. Its easy recall ... Furthermore, the VSOS-4P has a pulse operation for ...
... MONOLIGHT 3096 Microplate Luminometer has been ... bioluminescence and for,all measurements of glow ... reactions where the light remain nearly ... as well as for very fast ...
... Adept CE 4100 high pressure pump ... precision, with software drive compensation, reducing pulsing ... are selectable in 0.001mL steps. , The ... and bio-compatible., Pumps may be programmed from ...
Biology Products: